Inductive Bio

New York, New York, United States

AI drug discovery Drug Discovery Drug Development Life Sciences

Inductive Bio is a healthcare startup focused on accelerating drug discovery through state-of-the-art artificial intelligence (AI) and generative chemistry. The company has developed an advanced ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) model that leverages a large, diverse dataset from a pre-competitive data consortium to provide reliable predictions across the chemical space. Key products include the Beacon-1 AI model, which offers real-time ADMET predictions, and the Compass software, designed to assist chemists with actionable recommendations and efficient molecule design. Inductive Bio emphasizes a collaborative approach, integrating medicinal chemists and machine learning engineers to optimize the drug design process, ensuring that compounds meet desirable properties while reducing time and costs associated with drug development. The company's platforms prioritize data security and confidentiality, meeting rigorous standards while optimizing the design cycle for high-quality compounds.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Inductive Bio on @MedStartr Today #DrugDiscovery #DrugDevelopment #AllTherapeuticAreas #AIDrugDiscovery #LifeSciencesBiopharma #MedMo #MedStartrVentures

https://www.medstartr.ai/s/KLxnXgu_evU

Get Involved in Inductive Bio

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2022
Website: www.inductive.bio/

Disease Areas

Drug Discovery Drug Development All Therapeutic Areas

Technologies

AI Drug DiscoveryMolecular DesignPredictive AnalyticsComputational Drug Discovery

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Inductive Bio?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.